HK1057857A1 - Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof - Google Patents

Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof

Info

Publication number
HK1057857A1
HK1057857A1 HK04100053.0A HK04100053A HK1057857A1 HK 1057857 A1 HK1057857 A1 HK 1057857A1 HK 04100053 A HK04100053 A HK 04100053A HK 1057857 A1 HK1057857 A1 HK 1057857A1
Authority
HK
Hong Kong
Prior art keywords
proteins
inhibition
therapeutic
derived
biological activity
Prior art date
Application number
HK04100053.0A
Other languages
English (en)
Inventor
Beate Kehrel
Martin Brodde
Original Assignee
Hamburger Stiftung Zur Forderu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/de
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/de
Application filed by Hamburger Stiftung Zur Forderu filed Critical Hamburger Stiftung Zur Forderu
Publication of HK1057857A1 publication Critical patent/HK1057857A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
HK04100053.0A 2000-10-20 2004-01-05 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof HK1057857A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (de) 2000-10-20 2000-10-20 Inhibierung der pathogenen Wirkung oxidierter Proteine
DE2001148624 DE10148624A1 (de) 2001-10-02 2001-10-02 Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten
PCT/EP2001/012129 WO2002032445A2 (de) 2000-10-20 2001-10-19 Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus

Publications (1)

Publication Number Publication Date
HK1057857A1 true HK1057857A1 (en) 2004-04-23

Family

ID=26007431

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100053.0A HK1057857A1 (en) 2000-10-20 2004-01-05 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof

Country Status (14)

Country Link
EP (2) EP1328289B1 (el)
JP (1) JP4881535B2 (el)
AP (2) AP2781A (el)
AT (1) ATE406908T1 (el)
AU (1) AU2002215032A1 (el)
CA (1) CA2453140C (el)
CY (1) CY1110418T1 (el)
DE (1) DE50114289D1 (el)
DK (1) DK1328289T3 (el)
ES (1) ES2307662T3 (el)
HK (1) HK1057857A1 (el)
OA (1) OA12431A (el)
PT (1) PT1328289E (el)
WO (1) WO2002032445A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375601T3 (es) * 2003-04-25 2012-03-02 Hamburger Stiftung Zur Förderung Von Wissenschaft Und Kultur Lucha contra infecciones por virus de ih con plasma sangu�?neo humano oxidado con �?cido hipocloroso.
EP3549594A1 (en) * 2005-09-16 2019-10-09 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
DE102011003936A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (de) * 1988-06-11 1989-12-21 Behringwerke Ag Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung
CA2067364A1 (en) * 1989-10-06 1991-04-07 Eric T. Fossel Oxidized lipoproteins and methods for their preparation
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
AU7185191A (en) * 1990-01-08 1991-08-05 Schering Corporation Oxidized variants of gm-csf
CA2086921A1 (en) * 1990-07-18 1992-01-19 Eric T. Fossel Method for treating viral infections using oxidized lipoproteins
EP0728019A4 (en) 1993-11-08 1999-07-07 Peptide Delivery Systems Pty L MARKED DIAGNOSTIC COMPOSITIONS AND METHODS OF USE THEREOF
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
ATE385575T1 (de) 1997-06-20 2008-02-15 Leuven Res & Dev Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
WO2000028072A1 (en) * 1998-11-06 2000-05-18 Emory University Biomarkers for oxidative stress
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III

Also Published As

Publication number Publication date
EP1994941A2 (de) 2008-11-26
DE50114289D1 (de) 2008-10-16
AP2781A (en) 2013-10-31
OA12431A (en) 2006-04-19
EP1328289A2 (de) 2003-07-23
AP2009004857A0 (en) 2009-06-30
ATE406908T1 (de) 2008-09-15
AU2002215032A1 (en) 2002-04-29
CA2453140A1 (en) 2002-04-25
CY1110418T1 (el) 2015-04-29
PT1328289E (pt) 2008-12-10
AP2034A (en) 2009-08-28
ES2307662T3 (es) 2008-12-01
WO2002032445A3 (de) 2003-04-17
WO2002032445A2 (de) 2002-04-25
JP4881535B2 (ja) 2012-02-22
AP2003002795A0 (en) 2003-06-30
EP1328289B1 (de) 2008-09-03
JP2004511526A (ja) 2004-04-15
EP1994941A3 (de) 2012-07-25
CA2453140C (en) 2016-01-05
DK1328289T3 (da) 2008-12-15

Similar Documents

Publication Publication Date Title
ZA200004569B (en) Infusion of liquids into the human or animal body.
DE60233157D1 (de) Zweikammer-herzschrittmacher-system zur diagnose und behebung von arrhythmien
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
DE60020367D1 (de) Luftdurchlässige bekleidung zur komfortverbesserung des menschlichen körper
AU2002216273A1 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
IL196301A0 (en) Medicament for the treatment of hapatitis c
DE50011194D1 (de) Medizinisches Instrument zum Präparieren von Gewebe
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
EP1459759A4 (en) MEDICAMENT FOR THE MOBILIZATION OF PLURIPOTENTIAL STEM CELLS FROM TISSUE IN THE PERIPHERAL BLOOD
IL143699A0 (en) Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
AP2009004857A0 (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
EP1200133A4 (en) HANDLING OF FABRIC OR ORGAN TYPE USING THE NOTCH WAY
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
AU4204700A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
AU2001233954A1 (en) Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2001240820A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
ZA200202823B (en) Self-cleaving RNA sequences and their use for the control of protein synthesis.
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
AU2002222308A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular response
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
AU2002222307A1 (en) Proteins, genes and their use for diagnosis and treatment of cardiac response
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161019